Correlating HIV tropism with immunological response under combination antiretroviral therapy.

Abstract:

OBJECTIVES:A significant percentage of patients infected with HIV-1 experience only suboptimal CD4 cell recovery while treated with combination therapy (cART). It is still unclear whether viral properties such as cell tropism play a major role in this incomplete immune response. This study therefore intended to follow the tropism evolution of the HIV-1 envelope during periods of suppressive cART. METHODS:Viruses from two distinct patient groups, one with good and another one with poor CD4 recovery after 5 years of suppressive cART, were genotypically analysed for viral tropism at baseline and at the end of the study period. RESULTS:Patients with CCR5-tropic CC-motif chemokine receptor 5 viruses at baseline tended to maintain this tropism to the study end. Patients who had a CXCR4-tropic CXC-motif chemokine receptor 4 virus at baseline were overrepresented in the poor CD4 recovery group. Overall, however, the majority of patients presented with CCR5-tropic viruses at follow-up. CONCLUSIONS:Our data lend support to the hypothesis that tropism determination can be used as a parameter for disease progression even if analysed long before the establishment of a poorer immune response. Moreover, the lasting predominating CCR5-tropism during periods of full viral control suggests the involvement of cellular mechanisms that preferentially reduce CXCR4-tropic viruses during cART.

journal_name

HIV Med

journal_title

HIV medicine

authors

Bader J,Schöni-Affolter F,Böni J,Gorgievski-Hrisoho M,Martinetti G,Battegay M,Klimkait T,Swiss HIV Cohort Study.

doi

10.1111/hiv.12365

subject

Has Abstract

pub_date

2016-09-01 00:00:00

pages

615-22

issue

8

eissn

1464-2662

issn

1468-1293

journal_volume

17

pub_type

杂志文章
  • Late presentation of HIV infection: a consensus definition.

    abstract:OBJECTIVES:Across Europe, almost a third of individuals infected with HIV do not enter health care until late in the course of their infection. Surveillance to identify the extent to which late presentation occurs remains inadequate across Europe and is further complicated by the lack of a common clinical definition of...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2010.00857.x

    authors: Antinori A,Coenen T,Costagiola D,Dedes N,Ellefson M,Gatell J,Girardi E,Johnson M,Kirk O,Lundgren J,Mocroft A,D'Arminio Monforte A,Phillips A,Raben D,Rockstroh JK,Sabin C,Sönnerborg A,De Wolf F,European Late Presenter

    更新日期:2011-01-01 00:00:00

  • The role of tenofovir alafenamide in future HIV management.

    abstract::HIV infection has become a chronic condition rather than an acute life-threatening disease in developed countries, thanks to consistent innovation and evolution of effective interventions. This has altered HIV management and created new challenges. People living with HIV (PLWHIV) are living longer and so encounter com...

    journal_title:HIV medicine

    pub_type: 杂志文章,评审

    doi:10.1111/hiv.12401

    authors: Antela A,Aguiar C,Compston J,Hendry BM,Boffito M,Mallon P,Pourcher-Martinez V,Di Perri G

    更新日期:2016-05-01 00:00:00

  • Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response.

    abstract:OBJECTIVES:To investigate the concordance between any of the results of nine HIV-1 drug-resistance interpretation systems (ISs) and their ability to predict week 8 and week 24 virological responses to abacavir-containing combination therapy. PATIENTS AND METHODS:A total of 1306 HIV-infected patients with a viral load ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2008.00523.x

    authors: Cozzi-Lepri A,Standardization and Clinical Relevance of HIV Drug Resistance Testing Project for the Forum for Collaborative HIV Research.

    更新日期:2008-01-01 00:00:00

  • GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

    abstract:OBJECTIVES:To evaluate the benefits of therapeutic drug monitoring (TDM) in association with genotypic resistance testing and expert advice to optimize therapy in multiexperienced patients infected with HIV-1. METHODS:Patients with a viral load>1000 HIV-1 RNA copies/mL and an unchanged antiretroviral therapy regimen o...

    journal_title:HIV medicine

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2004.00234.x

    authors: Bossi P,Peytavin G,Ait-Mohand H,Delaugerre C,Ktorza N,Paris L,Bonmarchand M,Cacace R,David DJ,Simon A,Lamotte C,Marcelin AG,Calvez V,Bricaire F,Costagliola D,Katlama C

    更新日期:2004-09-01 00:00:00

  • Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.

    abstract:OBJECTIVE:More and more highly treatment-experienced patients are achieving viral suppression. However, the durability of suppression remains unclear. METHODS:Patients from Royal Free Hospital (London, UK) and JW Goethe University Hospital (Frankfurt, Germany) who had failed > or = 1 antiretroviral (ARV) regimen in al...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2008.00650.x

    authors: Smith CJ,Phillips AN,Dauer B,Johnson MA,Lampe FC,Youle MS,Tyrer M,Staszewski S

    更新日期:2009-01-01 00:00:00

  • Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure.

    abstract:OBJECTIVES:Two-drug antiretroviral regimens based on lamivudine (3TC) plus either a protease inhibitor (PI) or dolutegravir (DTG) are becoming increasingly popular in switch strategies. Our goal was to derive a predictive score for virological failure (VF). METHODS:We retrospectively analysed data for a cohort of 587 ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12759

    authors: Borghetti A,Moschese D,Cingolani A,Baldin G,Speziale D,Ciccullo A,Lombardi F,Emiliozzi A,Belmonti S,Antinori A,Cauda R,Di Giambenedetto S

    更新日期:2019-10-01 00:00:00

  • An analysis of patients' understanding of 'routine' preoperative blood tests and HIV screening. Is no news really good news?

    abstract:OBJECTIVES:Many patients may believe that HIV screening is included in routine preoperative work-ups. We examined what proportion of patients undergoing preoperative blood testing believed that they had been tested for HIV. METHODS:All patients hospitalized for elective orthopaedic surgery between January and December...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2012.00993.x

    authors: Albrecht E,Frascarolo P,Meystre-Agustoni G,Farron A,Gilliard N,Darling K,Cavassini M

    更新日期:2012-08-01 00:00:00

  • RNA amplification of the HIV-1 Pol and env regions on dried serum and plasma spots.

    abstract:BACKGROUND:Dried sample spots have molecular applications, but few data are available on conditions of HIV-1 RNA amplification. OBJECTIVES:To determine the impact of (i) the sample type (plasma or serum), (ii) various storage periods, (iii) transfer at ambient temperature of the dried spots via postal mail, and (iv) t...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2008.00604.x

    authors: Dachraoui R,Brand D,Brunet S,Barin F,Plantier JC

    更新日期:2008-08-01 00:00:00

  • Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

    abstract:OBJECTIVES:Efforts are needed to improve informed consent of participants in research. The Strategic Timing of AntiRetroviral Therapy (START) study provides a unique opportunity to study the effect of length and complexity of informed consent documents on understanding and satisfaction among geographically diverse part...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12230

    authors: Denning E,Sharma S,Smolskis M,Touloumi G,Walker S,Babiker A,Clewett M,Emanuel E,Florence E,Papadopoulos A,Sánchez A,Tavel J,Grady C,International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Grou

    更新日期:2015-04-01 00:00:00

  • HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care?

    abstract:OBJECTIVES:In the UK, free HIV care is provided through dedicated HIV clinics. Using the national cohort of men who have sex with men (MSM) with diagnosed HIV infection and estimates of the number of undiagnosed men, we assessed whether high retention in HIV care and treatment coverage is sufficient to reduce HIV trans...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12066

    authors: Brown AE,Gill ON,Delpech VC

    更新日期:2013-10-01 00:00:00

  • HIV/hepatitis C virus and HIV/hepatitis B virus coinfections protect against antiretroviral-related hyperlipidaemia.

    abstract:INTRODUCTION:Hyperlipidaemia is a recognized complication of HIV antiretroviral therapy. The interactions among HIV, viral hepatitis, antiretroviral therapies and lipids are poorly understood. METHODS:Ontario HIV Treatment Network Cohort Study participants with at least one lipid level after highly active antiretrovir...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2010.00897.x

    authors: Diong C,Raboud J,Li M,Cooper C,Ontario HIV Treatment Network Cohort Study Team.

    更新日期:2011-08-01 00:00:00

  • Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.

    abstract:OBJECTIVES:Single nucleotide polymorphisms in the cytochrome P450 (CYP) 2B6 gene have been associated with high interindividual variation in efavirenz pharmacokinetics. However, clinical data on the relationship of CYP2B6 polymorphisms with the occurrence of efavirenz-induced central nervous system (CNS) symptoms are l...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/hiv.12488

    authors: Gallien S,Journot V,Loriot MA,Sauvageon H,Morlat P,Reynes J,Reliquet V,Chêne G,Molina JM,ANRS 099 ALIZE trial study group.

    更新日期:2017-09-01 00:00:00

  • Risk factors for death among patients in French Guiana: 1996-2005.

    abstract::Risk factors for death in an HIV-infected cohort in French Guiana were studied in 1374 patients between 1996 and 2005. Of these patients, 48.5% were male and 76% were immigrants. Covariates were measured at the time of consultation. There were 223 deaths. Addictions [adjusted hazard ratio (HR)=13; 95% confidence inter...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00492.x

    authors: Nacher M,Huber F,El Guedj M,Vaz T,Magnien C,Djossou F,Randrianjohany A,Alvarez F,Couppié P

    更新日期:2007-10-01 00:00:00

  • Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.

    abstract:OBJECTIVES:Abacavir (ABC) selects for four mutations (K65R, L74V, Y115F and M184V) in HIV-1 reverse transcriptase (RT), both in vitro and during monotherapy in vivo. The aim of this analysis was to compare the selection of these and other nucleoside reverse transcriptase inhibitor (NRTI)-associated mutations by ABC-con...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2004.00243.x

    authors: Lanier ER,Givens N,Stone C,Griffin P,Gibb D,Walker S,Tisdale M,Irlbeck D,Underwood M,St Clair M,Ait-Khaled M

    更新日期:2004-11-01 00:00:00

  • Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.

    abstract:OBJECTIVES:The aim of the study was to determine the factors that may contribute to decreases in bone mineral density (BMD) in patients with AIDS. METHODS:This was a prospective, non-randomized study. Dual X-ray absorptiometry (DXA) was used to determine the BMD of the lumbar spine, femoral neck and distal radius in t...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2007.00525.x

    authors: Rivas P,Górgolas M,García-Delgado R,Díaz-Curiel M,Goyenechea A,Fernández-Guerrero ML

    更新日期:2008-02-01 00:00:00

  • The association of adiposity with kidney function decline among HIV-infected adults: findings from the Fat Redistribution and Metabolic Changes in HIV Infection (FRAM) study.

    abstract:OBJECTIVES:The aim of the study was to investigate the association of adiposity with longitudinal kidney function change in 544 HIV-infected persons in the Study of Fat Redistribution and Metabolic Change in HIV infection (FRAM) cohort over 5 years of follow-up. METHODS:The regional distribution of muscle and adipose ...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12196

    authors: Malkina A,Scherzer R,Shlipak MG,Bacchetti P,Tien PC,Grunfeld C,Kosmiski L,Peralta CA

    更新日期:2015-03-01 00:00:00

  • Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa.

    abstract:OBJECTIVES:Socio-economic factors and lifestyle are known to differ across geographies and populations, which may result in distinct risk profiles for cardiovascular disease (CVD). This study assessed carotid intima-media thickness (CIMT), a proxy for CVD, and its determinants in two groups of people living with HIV (P...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12831

    authors: Roozen G,Vos AG,Tempelman HA,Venter W,Grobbee DE,Scheuermaier K,Klipstein-Grobusch K

    更新日期:2020-07-01 00:00:00

  • Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis.

    abstract:OBJECTIVES:Anaemia represents a common toxicity with amphotericin B-based induction therapy in HIV-infected persons with cryptococcal meningitis. We sought to examine the impact of amphotericin-related anaemia on survival. METHODS:We used data from Ugandan and South African trial participants to characterize the varia...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12387

    authors: Tugume L,Morawski BM,Abassi M,Bahr NC,Kiggundu R,Nabeta HW,Hullsiek KH,Taseera K,Musubire AK,Schutz C,Muzoora C,Williams DA,Rolfes MA,Meintjes G,Rhein J,Meya DB,Boulware DR

    更新日期:2017-01-01 00:00:00

  • Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific.

    abstract:OBJECTIVES:To assess second-line antiretroviral therapy (ART) virological failure and HIV drug resistance-associated mutations (RAMs), in support of third-line regimen planning in Asia. METHODS:Adults > 18 years of age on second-line ART for ≥ 6 months were eligible. Cross-sectional data on HIV viral load (VL) and gen...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.13006

    authors: Ross J,Jiamsakul A,Kumarasamy N,Azwa I,Merati TP,Do CD,Lee MP,Ly PS,Yunihastuti E,Nguyen KV,Ditangco R,Ng OT,Choi JY,Oka S,Sohn AH,Law M

    更新日期:2020-11-05 00:00:00

  • Monitoring the HIV continuum of care in key populations across Europe and Central Asia.

    abstract:OBJECTIVES:The aim of the study was to measure and compare national continuum of HIV care estimates in Europe and Central Asia in three key subpopulations: men who have sex with men (MSM), people who inject drugs (PWID) and migrants. METHODS:Responses to a 2016 European Centre for Disease Prevention and Control (ECDC)...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12603

    authors: Brown AE,Attawell K,Hales D,Rice BD,Pharris A,Supervie V,Van Beckhoven D,Delpech VC,An der Heiden M,Marcus U,Maly M,Noori T

    更新日期:2018-05-08 00:00:00

  • HIV testing strategies outside of health care settings in the European Union (EU)/European Economic Area (EEA): a systematic review to inform European Centre for Disease Prevention and Control guidance.

    abstract:OBJECTIVES:In recent years, new technologies and new approaches to scale up HIV testing have emerged. The objective of this paper was to synthesize the body of recent evidence on strategies aimed at increasing the uptake and coverage of HIV testing outside of health care settings in the European Union (EU)/European Eco...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12807

    authors: Croxford S,Tavoschi L,Sullivan AK,Combs L,Raben D,Delpech V,Jakobsen SF,Amato-Gauci AJ,Desai S

    更新日期:2020-03-01 00:00:00

  • Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE s

    abstract:OBJECTIVES:We assessed whether changes at week 12 in markers of bone turnover, inflammation, and immune activation were associated with clinically important (≥ 5%) bone mineral density (BMD) loss from baseline to week 48 at the proximal femur (hip) and lumbar spine in the SECOND-LINE study. METHODS:We measured concent...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12882

    authors: Mwasakifwa GE,Amin J,White CP,Center JR,Kelleher A,Boyd MA

    更新日期:2020-09-01 00:00:00

  • Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma.

    abstract:BACKGROUND:AIDS-related lymphoma (ARL) remains the main cause of AIDS-related deaths in the combined antiretroviral therapy (cART) era. Although most ARLs are associated with the Epstein-Barr virus (EBV), whether patients with high EBV burden are more at risk of developing ARL is unknown. This study investigated the re...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/j.1468-1293.2012.00998.x

    authors: Leruez-Ville M,Seng R,Morand P,Boufassa F,Boue F,Deveau C,Rouzioux C,Goujard C,Seigneurin JM,Meyer L

    更新日期:2012-09-01 00:00:00

  • Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes.

    abstract:OBJECTIVES:Antiretroviral therapy (ART) has been associated with unfavourable lipid profile changes and increased risk of cardiovascular disease (CVD). With a growing population on ART in South Africa, there has been concern about the increase in noncommunicable diseases such as CVD. We determined risk factors associat...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12495

    authors: Jamieson L,Evans D,Brennan AT,Moyo F,Spencer D,Mahomed K,Maskew M,Long L,Rosen S,Fox MP

    更新日期:2017-09-01 00:00:00

  • Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

    abstract:OBJECTIVES:The aim of the study was to describe growth and body composition changes in HIV-positive children after they had initiated or changed antiretroviral therapy (ART) and to correlate these with viral, immune and treatment parameters. METHODS:Ninety-seven prepubertal HIV-positive children were observed over 48 ...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2010.00823.x

    authors: Chantry CJ,Cervia JS,Hughes MD,Alvero C,Hodge J,Borum P,Moye J Jr,PACTG 1010 Team.

    更新日期:2010-10-01 00:00:00

  • Cushing's syndrome secondary to inhaled corticosteroids mimicking HIV-associated lipodystrophy.

    abstract::We report the case of an asthmatic man with HIV infection who was initially diagnosed with HIV treatment-associated lipodystrophy. Further investigations showed he had Cushing's syndrome secondary to 1600 microg of budesonide dry powder inhaler. Cushing's syndrome has not been reported previously on this normal dose o...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1046/j.1468-1293.2001.00058.x

    authors: le Roux CW,Beckles MA,Besser GM,Pinching AJ,Davison AG

    更新日期:2001-04-01 00:00:00

  • Polypharmacy and potential drug-drug interactions for people with HIV in the UK from the Climate-HIV database.

    abstract:OBJECTIVES:People with HIV (PWHIV) are likely to need therapies for comorbidities as they age. We assessed risk of drug-drug interactions (DDIs) in PWHIV. METHODS:The Climate-HIV electronic recording system was used to cross-sectionally analyse records from PWHIV aged ≥ 18 years attending four UK HIV units with a curr...

    journal_title:HIV medicine

    pub_type: 杂志文章

    doi:10.1111/hiv.12879

    authors: Okoli C,Schwenk A,Radford M,Myland M,Taylor S,Darley A,Barnes J,Fox A,Grimson F,Reeves I,Munshi S,Croucher A,Boxall N,Benn P,Paice A,van Wyk J,Khoo S

    更新日期:2020-09-01 00:00:00

  • Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19).

    abstract:BACKGROUND:More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005. DESIGN AND METHODS:In 2005, 34 departments prospectively recorded all dea...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2008.00686.x

    authors: Rosenthal E,Salmon-Céron D,Lewden C,Bouteloup V,Pialoux G,Bonnet F,Karmochkine M,May T,François M,Burty C,Jougla E,Costagliola D,Morlat P,Chêne G,Cacoub P,Mortavic\/Mortalité 2005 Study Group.

    更新日期:2009-05-01 00:00:00

  • New mutations associated with resistance not detected following zidovudine monotherapy in pregnancy when used in accordance with British HIV Association guidelines.

    abstract:OBJECTIVES:To determine whether mutations conferring drug resistance are detectable after zidovudine monotherapy (ZDVm) in pregnancy, using both standard genotyping and more sensitive cloning assays. METHODS:Post-delivery samples from women meeting the British HIV Association guidelines criteria for the use of ZDVm in...

    journal_title:HIV medicine

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1468-1293.2008.00594.x

    authors: Read P,Costelloe S,Mullen J,O'Shea S,Lyons F,Hay P,Welch J,Larbalestier N,Taylor G,de Ruiter A

    更新日期:2008-08-01 00:00:00

  • Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.

    abstract:OBJECTIVE:Study 903 was a 144-week, randomized, double-blind, active-controlled study of tenofovir disoproxil fumarate (TDF) therapy in treatment-naive HIV-1-infected patients. Patients received either TDF (n = 299) or stavudine (d4T) (n = 301) with lamivudine (3TC) and efavirenz (EFV). Resistance analyses were perform...

    journal_title:HIV medicine

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1468-1293.2006.00404.x

    authors: Margot NA,Lu B,Cheng A,Miller MD,Study 903 Team.

    更新日期:2006-10-01 00:00:00